Resultados da pesquisa - Huang, Dennis Chin-Lun

A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma Por Yen, Chia-Jui, Kim, Tae-You, Feng, Yin-Hsun, Chao, Yee, Lin, Deng-Yn, Ryoo, Baek-Yeol, Huang, Dennis Chin-Lun, Schnell, David, Hocke, Julia, Loembé, Arsène-Bienvenu, Cheng, Ann-Lii

Obter o texto integral Obter o texto integral Obter o texto integral

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors Por Park, Keunchil, Tan, Daniel Shao Weng, Su, Wu-Chou, Cho, Byoung Chul, Kim, Sang-We, Lee, Ki Hyeong, Wang, Chin-Chou, Seto, Takashi, Huang, Dennis Chin-Lun, Jung, Helen Hayoun, Hsu, Ming-Chi, Bogenrieder, Thomas, Lin, Chia-Chi

Obter o texto integral Obter o texto integral Obter o texto integral

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies Por Passaro, Antonio, de Marinis, Filippo, Tu, Hai-Yan, Laktionov, Konstantin K., Feng, Jifeng, Poltoratskiy, Artem, Zhao, Jun, Tan, Eng Huat, Gottfried, Maya, Lee, Victor, Kowalski, Dariusz, Yang, Cheng Ta, Srinivasa, BJ, Clementi, Laura, Jalikop, Tejaswini, Huang, Dennis Chin Lun, Cseh, Agnieszka, Park, Keunchil, Wu, Yi-Long

Obter o texto integral Obter o texto integral Obter o texto integral

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic bre... Por Schmid, Peter, Sablin, Marie-Paule, Bergh, Jonas, Im, Seock-Ah, Lu, Yen-Shen, Martínez, Noelia, Neven, Patrick, Lee, Keun Seok, Morales, Serafín, Pérez-Fidalgo, J. Alejandro, Adamson, Douglas, Gonçalves, Anthony, Prat, Aleix, Jerusalem, Guy, Schlieker, Laura, Espadero, Rosa-Maria, Bogenrieder, Thomas, Huang, Dennis Chin-Lun, Crown, John, Cortés, Javier

Obter o texto integral Obter o texto integral Obter o texto integral

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours Por de Bono, Johann, Lin, Chia-Chi, Chen, Li-Tzong, Corral, Jesus, Michalarea, Vasiliki, Rihawi, Karim, Ong, Michael, Lee, Jih-Hsiang, Hsu, Chih-Hung, Yang, James Chih-Hsin, Shiah, Her-Shyong, Yen, Chia-Jui, Anthoney, Alan, Jove, Maria, Buschke, Susanne, Fuertig, René, Schmid, Ulrike, Goeldner, Rainer-Georg, Strelkowa, Natalja, Huang, Dennis Chin-Lun, Bogenrieder, Thomas, Twelves, Chris, Cheng, Ann-Lii

Obter o texto integral Obter o texto integral Obter o texto integral

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China Por Tu, Hai-Yan, Feng, Jifeng, Shi, Meiqi, Zhao, Jun, Wang, Yuyan, Chang, Jianhua, Wang, Jialei, Cheng, Ying, Zhu, Jing, Tan, Eng-Huat, Li, Kai, Zhang, Yiping, Lee, Victor, Yang, Cheng-Ta, Su, Wu-Chou, Lam, David Chi-Leung, Srinivasa, B. J., Rajappa, Senthil, Ho, Ching-Liang, Lam, Kwok Chi, Hu, Yi, Bondarde, Shailesh Arjun, Liu, Xiaoqing, Tian, Yahui, Xue, Zhiyi, Cseh, Agnieszka, Huang, Dennis Chin-Lun, Zhou, Caicun, Wu, Yi-Long

Obter o texto integral Obter o texto integral Obter o texto integral